Hepatitis Drug Development Pipeline Review, 2017

NEW YORK, Aug. 3, 2017 /PRNewswire/ -- Hepatitis Drug Development Pipeline Review, 2017

Summary
Hepatitis is a contagious viral infection affecting the liver, which may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis typically include dialysis, organ transplant and blood transfusion and theoffspring of an infected mother also has high chances of contracting the disease.


Read the full report: http://www.reportlinker.com/p05043171/Hepatitis-Drug-Development-Pipeline-Review.html

Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; there are a total of seven products in development for hepatitis A, by four companies and two academic institutions. Beijing Minhai Biotechnology are fielding two pipeline products in this area, while all other companies are fielding only one. In hepatitis D there are a total of 12 products in development, by nine companies and one academic institution. Key companies operating in this pipeline space include EigerBioPharmaceuticalsand Replicor.

Many of the companies who are actively fielding products in the larger two hepatitis subtypes are simultaneously developing products for both.

There are a total of 182 products in development for hepatitis B, by 110 companies and 14 academic institutions. Key companies operating in this pipeline space include Arbutus Biopharma, F. Hoffmann-La Roche, Johnson & Johnson, Assembly Biosciences, Gilead Sciences and InstitutoButantan. There are a total of 199 products in development for hepatitis C, by 92 companies and 34 academic institutions. Key companies operating in this pipeline space include Merck & Co, AbbVie, Johnson & Johnson, Gilead Sciences, Cocrystal Pharma, Bristol-Myers Squibb and F. Hoffmann-La Roche.

While in hepatitis A, B and D, viral surface antigens and interferons are commonly targeted, a far wider range of proteins, including non-structural proteins, are the most common targets in hepatitis C.

The report "Hepatitis Drug Development Pipeline Review, 2017", provides an overview of the hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, B, C and D, and features dormant and discontinued projects.

Scope
- Which companies are the most active within the pipeline for hepatitis therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of hepatitis?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Read the full report: http://www.reportlinker.com/p05043171/Hepatitis-Drug-Development-Pipeline-Review.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

_________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/hepatitis-drug-development-pipeline-review-2017-300499551.html

SOURCE Reportlinker